infliximab
Commercial- Indications
- Inflammatory diseases
Company intelligence / Profile preview
Shandong Kexing Bioproducts is a leading Chinese biopharmaceutical manufacturer specializing in recombinant protein therapeutics such as erythropoietin (“EPOSINO”), granulocyte colony-stimulating factor (“WHITE-C”), interferon α1b (“SINOGEN”), long/short acting growth hormones, and microecological agents like combined Clostridium butyricum + Bifidobacterium powder. Its products are widely used for anemia, neutropenia, immune modulation/infection control, gastrointestinal disorders and more. The company has achieved commercial success with approvals since at least the early 2000s in China; it continues to expand its R&D pipeline with innovative biologics including Fc-fusion long acting growth hormone.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Kexing Bioproducts.